Abstract Library

#2706 A New Possibility in SI-NET Surgery by Using a New β- Probe and 90Y-DOTATOC: A Pilot Study

Introduction: In neuroendocrine tumor (NET), complete surgery could better the prognosis of this disease: radioguided surgery (RGS) with beta-radioisotopes, as 90Y, is a novel approach focused on developing a new probe which, detecting electrons and operating with low background, provides a clearer delineation of the margins of lesions with low radiation exposition for surgeons.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Grana C

Authors: Grana C, Bertani E, Collamati F, Faccini R, Pisa E,

Keywords: Small intestine neuroendocrine tumors, liver metastases, β- probe, 90Y-DOTATOC,

#1863 Outcome of Surgical Resection after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT) for Pancreatic Neuroendocrine Neoplasms: A Case-Matched Analysis

Introduction: Neoadjuvant Peptide receptor radionuclide therapy (NPRRT) can be an option for advanced pancreatic neuroendocrine neoplasms (PNEN) before surgery. Is not clear if NPRRT increases postoperative morbidity

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Muffatti F, Partelli S, Andreasi V, Bertani E, Bartolomei M,

Keywords: neoadjuvant PRRT, PNEN, surgery,

#1348 Resectable Primary Tumor in Patients with Pancreatic Neuroendocrine Tumors Located to the Body or Tail and Unresectable Liver Metastases: Does Distal Pancreatectomy Improve Survival?

Introduction: The role of primary tumor surgery in pancreatic neuroendocrine tumor (PNET) with unresectable liver metastases is controversial and international guidelines do not recommend surgery in that setting of patients

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Bertani E

Authors: Bertani E, Fazio N, Grana C, Chiappa A, Biffi R,

Keywords: PNET, surgery, liver metastases, distal pancreatectomy, survival,

#1336 Resection of the Primary Tumor Prior to Peptide Receptor Radionuclide Therapy Improves Treatment Response and Progression-free Survival in Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases

Introduction: A low burden of disease represents an independent favorable prognostic factor of response to peptide receptor radionuclide therapy (PRRT) in patients affected by gastro-entero-pancreatic neuroendocrine tumors. However it is not clear whether this is due to a lower diffusion of the disease or thanks to debulking surgery

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Bertani E

Authors: Bertani E, Fazio N, Grana C, Bodei L, Funicelli L,

Keywords: PNET, PRRT, debulking surgery, PFS,

#817 Surgery after Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Introduction: There are a few case reports on surgery after peptide receptor radionuclide therapy (PRRT).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Bertani E, Chiappa A, Fazio N, Grana C, Bodei L,

Keywords: neuroendocrine tumors, peptide receptor radionuclide therapy, surgery, survival, progression-free survival,